Click here to read the articles and download the PDF

Pharmaceutical Commerce - April 2022

Creating positive experiences and other patient-focused strategies for sponsors to consider when planning and executing cancer studies

Empowering Patients in Oncology Trials

Not quite specialty, not quite retail: Cost-effective access and support strategies for a growing, yet underserved, treatment market

Adding Might to ‘Specialty Lite’

The patient-first, pharmacy-first hub model optimizes outcomes and improves care journey for patients with rare disease

Success with SP Solutions

Articles

Company anticipating to double global network size by end of the year

Tower Cold Chain Opens Los Angeles Location

Among functions, 80,000 square-foot space will house a 'Center of Excellence'

Cytiva Opening a New CGT Switzerland Facility

Location will feature aseptic fill-finish technology

PCI Pharma Services to Invest $100 Million in New Hampshire Facility

Deal for PROPENSITY4 grows company’s data analytics knowledge

Ashfield Engage Acquires Data Solutions Provider

Pfizer to commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine

Pfizer to Acquire Biohaven Pharmaceuticals

Per supply chain agreement, CDMO will provide analytical product support 

Alcami Forms Multi-year Partnership with Civica Rx

Steven Lucio is responsible for providing education to member organizations and supporting their efforts on various clinical practice topics, including improving medication safety, mitigating the impact of drug shortages, benchmarking pharmacy costs for key drug classes, evaluating the expense of high-cost biologics and preparing for the future development of biosimilar medications.

 currently serves as Vizient’s senior regulatory affairs and public policy director. In this role, she identifies and responds to legislative and regulatory developments of most interest to Vizient members. Medicare reimbursement and prescription drug policy are among the topics which Jenna focuses on at Vizient.

FDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern

Exclusivity Creates Challenges in Price, Access for Long-used Medications

Among efforts, part of center’s focus revolves providing tools for product commercialization 

Matica Bio Opens New Texas CGT Facility 

New partnership focused on improving quality of care, patient outcomes and safety in health systems 

URAC and HOSP Announce Strategic Relationship

Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines

Featured Content

Pharmaceutical Commerce - April 2022

Empowering Patients in Oncology Trials

Adding Might to ‘Specialty Lite’

Success with SP Solutions